2,213 reports of this reaction
2.0% of all TERIFLUNOMIDE reports
#13 most reported adverse reaction
MULTIPLE SCLEROSIS is the #13 most commonly reported adverse reaction for TERIFLUNOMIDE, manufactured by Genzyme Corporation. There are 2,213 FDA adverse event reports linking TERIFLUNOMIDE to MULTIPLE SCLEROSIS. This represents approximately 2.0% of all 108,080 adverse event reports for this drug.
TERIFLUNOMIDE has an overall safety score of 78 out of 100. Patients taking TERIFLUNOMIDE who experience multiple sclerosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS is a less commonly reported adverse event for TERIFLUNOMIDE, but still significant enough to appear in the safety profile.
In addition to multiple sclerosis, the following adverse reactions have been reported for TERIFLUNOMIDE:
The following drugs have also been linked to multiple sclerosis in FDA adverse event reports:
MULTIPLE SCLEROSIS has been reported as an adverse event in 2,213 FDA reports for TERIFLUNOMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS accounts for approximately 2.0% of all adverse event reports for TERIFLUNOMIDE, making it a notable side effect.
If you experience multiple sclerosis while taking TERIFLUNOMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.